Novartis announces FDA approval of Gilenya as the first disease-modifying therapy for pediatric relapsing multiple sclerosis Read more
miRagen Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides Read more